Overview Key strengths Key risks Good scale and product diversity across seven business segments. Competition with products from larger companies such as Becton Dickinson&Co., Medtronic PLC, Boston Scientific Corp., and others. Participation in high growth segments such as interventional cardiology/radiology and interventional urology. Ongoing inflationary pressures. Solid track record of acquisition integration. More aggressive acquisition strategy compared with similarly rated peers. Teleflex increased its revenue by 6.6% (reported basis) in 2023, driven by strong growth within the interventional and original equipment manufacturing (OEM) product areas, partially offset by weaker performance in areas such as interventional urology and anesthesia. In 2024, we project the company?s revenue will increase 4%-5%, driven by high-single-digit percent growth in its interventional and interventional
